Gwendolyn Wu is a reporter at BioPharma Dive. She specializes in covering biotech startups, venture capital, and the healthcare ecosystem, with a keen focus on the intersection of medicine and business. Gwendolyn's work has been featured in notable publications including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
By: Gwendolyn Wu
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
By: Gwendolyn Wu
The startup, which is building a database of biological interactions found in nature, also secured $60 million in funding from a group of life sciences and tech investors.
By: Gwendolyn Wu
The offering will fund testing of a potential rival to Amgenâs Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
The latest biotech arrival on Nasdaq entered the clinic last month with its lead drug candidate, a treatment for hypoparathyroidism.
The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.
By: Gwendolyn Wu
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its âoptions openâ regarding a future IPO, its CEO said.
(833) 317-6278 
